Welcome to our dedicated page for Talphera news (Ticker: $tlph), a resource for investors and traders seeking the latest updates and insights on Talphera stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talphera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talphera's position in the market.
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, at 10:40 a.m. ET. The management will engage in a fireside chat format to discuss the company's innovative therapies developed for medically supervised settings. This session aims to provide insights into Talphera's business strategies and future plans. Attendees can join the webcast through a provided link.
Talphera (Nasdaq: TLPH) announced its Q1 2024 financial results and provided a corporate update. The company reported cash and investments of $18.6 million as of March 31, 2024. Combined R&D and SG&A expenses were $4.2 million, down from $5.3 million in Q1 2023, due to reduced headcount from divesting DSUVIA. Net loss from continuing operations was $4.0 million, compared to net income of $0.1 million in Q1 2023, due to changes in the fair value of the company's warrant liability. The NEPHRO CRRT study is set to enroll its first patients in Q2 2024. Dr. Shakil Aslam joins as Chief Development Officer on May 20, 2024.
Talphera, Inc. (NASDAQ: TLPH) will release its first quarter 2024 financial results on May 14, 2024, followed by a live webcast and conference call to discuss the results and provide a business update. The webcast can be accessed on the company's website, and the conference call details are provided for investors.